CAR‑T Q&A | Who Is Eligible for CAR‑T Therapy? What Pre‑Treatment Preparations Are Required?
“I’ve heard CAR‑T works for leukaemia and lymphoma. Am I a suitable candidate?” “I’ve decided to receive CAR‑T, what preparations should I make in advance?” “What steps lie between treatment decision‑making and actual cell infusion?”
After learning basic facts about CAR‑T, numerous patients and their families face these practical questions. This article elaborates on eligible patient groups, pre‑treatment evaluation and preparation, as well as the full workflow from leukapheresis to infusion, helping patients stay well‑informed.
I. Who qualifies for CAR‑T therapy?
At present, CAR‑T therapy is mainly applied in haematological oncology. With eight CAR‑T products approved successively in China, their indications cover multiple relapsed/refractory haematological malignancies.
From the patient’s perspective, seek professional assessment from a CAR‑T specialist team if you meet all three criteria below:
Matching disease type: Suffering from conditions covered by approved CAR‑T indications, mainly including B‑cell leukaemia, lymphoma and multiple myeloma.
Appropriate lines of prior treatment: Comply with indications of corresponding commercial products. Some patients may be evaluated at second‑line therapy, while most receive CAR‑T after relapse or refractoriness following multiple lines of treatment.
Acceptable physical condition: Fair performance status, no severe active infection, and functional vital organs (heart, liver, kidneys) that can tolerate treatment.
Specifically, major eligible populations are as follows:
Relapsed/refractory large B‑cell lymphoma (diffuse large B‑cell lymphoma, primary mediastinal large B‑cell lymphoma, high‑grade B‑cell lymphoma, etc.): One of the earliest and most widely adopted CAR‑T indications. CAR‑T serves as a key therapeutic option for patients failing two or more lines of systemic therapy.
Relapsed/refractory B‑cell acute lymphoblastic leukaemia (B‑ALL): Delivers remarkable outcomes for both adult and paediatric patients.
Relapsed/refractory multiple myeloma: BCMA‑targeted CAR‑T products bring new hope for patients with multi‑line treatment failure.
Other subtypes: Mantle‑cell lymphoma and follicular lymphoma also have corresponding approved indications. For T‑cell acute lymphoblastic leukaemia, T‑cell lymphoma and Hodgkin’s lymphoma, CAR‑T is still under clinical investigation.
💡 Key Reminder: Do not consider CAR‑T only when all other treatment options are exhausted. Seek early assessment from CAR‑T experts if chemotherapy shows poor response or early‑stage relapse occurs.
II. Evaluations and preparations before CAR‑T treatment
CAR‑T therapy is not accessible upon request. Rigorous assessment and adequate pre‑treatment preparation are prerequisites for safety and efficacy, covering three major segments:
1. Comprehensive baseline assessment
Prior to initiating CAR‑T, clinicians carry out full‑workup examinations:
Disease assessment: Bone‑marrow aspiration, lumbar puncture, PET‑CT and other imaging tests to confirm tumour subtype, burden and distribution.
Physical function assessment: Tests including electrocardiogram, echocardiogram, complete blood count, liver and kidney function panels to verify tolerance for debulking and lymphodepleting chemotherapy.
Infection screening: Rule out active infection. Any ongoing infection must be controlled before cell infusion.
Performance‑status evaluation: Physicians assess daily activity capacity via ECOG scoring. Better physical fitness correlates with higher tolerance against adverse events.
2. Pre‑treatment medication management
Discontinuation of specific drugs: Certain chemotherapeutic agents require adequate wash‑out periods before T‑cell leukapheresis, to preserve T‑cell quality and secure successful CAR‑T manufacturing. Studies indicate bendamustine administered within six months prior to leukapheresis raises risks of CAR‑T production failure; recent use should be avoided.
Proactive lymphocyte cryopreservation: For high‑risk patients, collect and preserve healthy lymphocytes in advance to prevent T‑cell impairment caused by subsequent multi‑line chemotherapy.
3. Select the right therapeutic agent — match the appropriate CAR‑T product
Seven CAR‑T products have gained regulatory approval in China, predominantly targeting CD19 (for B‑cell leukaemia and lymphoma) and BCMA (for multiple myeloma). Each product has distinct indications. At experienced centres such as Beijing Boren Hospital, clinicians select optimal CAR‑T products tailored to each patient’s disease profile, subtype and target antigen expression.
III. Full workflow of CAR‑T treatment
Manufacturing typically takes 2‑3 weeks from T‑cell collection to infusion. Total timeline including pre‑treatment workup and hospitalisation shall follow attending physicians’ arrangements. Key stages are listed below:
T‑cell collection: Isolate sufficient T‑cells from peripheral blood of patients or donors via apheresis.
Laboratory manufacturing: Collected T‑cells are sent to a GMP‑compliant laboratory for genetic modification and ex‑vivo expansion to generate CAR‑T cells.
Bridging therapy: Short‑course chemotherapy or targeted therapy is administered for patients with high tumour burden or rapidly progressing disease during manufacturing waiting periods, to reduce tumour load and create favourable conditions for infusion. Bridging therapy may be omitted for stable cases.
Lymphodepleting conditioning: Patients are hospitalised to receive lymphodepleting chemotherapy. It eliminates endogenous lymphocytes to make space for robust CAR‑T‑cell expansion in vivo.
CAR‑T infusion: Infuse manufactured CAR‑T cells into the patient’s bloodstream, in a procedure similar to blood transfusion.
In‑hospital monitoring: Critical risk‑surveillance phase. Medical teams closely track vital signs and promptly manage adverse reactions.
Closing Remarks
CAR‑T represents a systematic therapeutic pathway: precise assessment → cell collection & manufacturing → bridging tumour control → lymphodepleting conditioning → post‑infusion monitoring. Every step is closely interconnected. Therefore, treatment by an experienced CAR‑T team is of vital importance.
With nearly nine years of clinical practice, Beijing Boren Hospital has accumulated almost 5 000 clinical study and treatment cases, establishing a full‑cycle diagnosis‑and‑treatment system. A specialised team not only enables patients to access CAR‑T therapy, but also ensures optimal clinical outcomes.
Comments